Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1705 · 1 trial · 1 indication
To assess the safety and tolerability of AZD1705 following subcutaneous administration of single ascending doses (Part A) and multiple ascending doses (Part B) in participants with dyslipidemia
| Arm | Type | Description |
|---|---|---|
| Part A1 (AZD1705) | ACTIVE_COMPARATOR | Non-Asian participants will receive AZD1705 subcutaneously on Day 1. |
| Part A2 (AZD1705) | ACTIVE_COMPARATOR | Japanese participants will receive AZD1705 subcutaneously on Day 1. |
| Part A3 (AZD1705) | ACTIVE_COMPARATOR | Chinese participants will receive AZD1705 subcutaneously on Day 1. |
| Part B1 (AZD1705) | ACTIVE_COMPARATOR | Non-Asian participants who may or may not be receiving moderate- or high-intensity statin therapy will receive AZD1705 subcutaneously on Day 1 and Day 29. |
| Part B2 (AZD1705) | ACTIVE_COMPARATOR | Japanese participants not receiving statin therapy will receive AZD1705 subcutaneously on Day 1 and Day 29. |
| Part B3 (AZD1705) | ACTIVE_COMPARATOR | Participants who may or may not be receiving moderate- or high-intensity statin therapy and with the additional diagnosis of type 2 diabetes will receive AZD1705 subcutaneously on Day 1 and Day 29. |
| Part A1 (Placebo) | PLACEBO_COMPARATOR | Non-Asian participants will receive placebo on Day 1. |
| Part A2 (Placebo) | PLACEBO_COMPARATOR | Japanese participants will receive placebo on Day 1. |
| Part A3 (Placebo) | PLACEBO_COMPARATOR | Chinese participants will receive placebo on Day 1. |
| Part B1 (Placebo) | PLACEBO_COMPARATOR | Non-Asian participants who may or may not be receiving moderate- or high-intensity statin therapy will receive placebo on Day 1 and Day 29. |
| Part B2 (Placebo) | PLACEBO_COMPARATOR | Japanese participants not receiving statin therapy will receive placebo on Day 1 and Day 29. |
| Part B3 (Placebo) | PLACEBO_COMPARATOR | Participants who may or may not be receiving moderate- or high-intensity statin therapy and with the additional diagnosis of type 2 diabetes will receive placebo on Day 1 and Day 29. |
| Name | Type | Description |
|---|---|---|
| AZD1705 | DRUG | Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B. |
| Placebo | OTHER | Participants will receive placebo on Day 1 in Part A, and Days 1 and 29 in Part B. |
Inclusion Criteria: * Male and female of non-childbearing potential participants with suitable veins for cannulation or repeated venipuncture. * All females must have a negative pregnancy test. * Participants with elevated lipids. * BMI between 18 and 35 kg/m\^2. Part B1 - May or may not be receiv...
AZD1705 is an investigational small molecule being developed for cardiovascular conditions, specifically for the treatment of dyslipidemia. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
The specific molecular target of AZD1705 has not been disclosed. It is a small molecule being studied for its effects on lipid levels in patients with dyslipidemia, a condition characterized by abnormal amounts of lipids in the blood.
AZD1705 is being developed by AstraZeneca PLC, a global biopharmaceutical company listed on the stock exchange under the ticker symbol AZN.
AZD1705 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved for any use. The ongoing Phase 1 trial is active but not recruiting participants.
AZD1705 is being studied in a Phase 1 clinical trial with the identifier NCT06238466. This trial is investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD1705 in participants with dyslipidemia. The study is randomized, double-blind, and placebo-controlled, with an enrollment of 98 participants.
No alternative names for AZD1705 have been disclosed. It is identified solely by its developmental code name AZD1705.